PBI 1402

Drug Profile

PBI 1402

Alternative Names: PBI-1402

Latest Information Update: 22 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ProMetic Life Sciences
  • Class Chemoprotectants; Colony-stimulating factors
  • Mechanism of Action Colony stimulating factor stimulants; Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Anaemia
  • No development reported Kidney disorders

Most Recent Events

  • 22 Sep 2015 Phase-I/II development was completed for Anaemia in Canada and Eastern Europe
  • 18 Oct 2010 PBI 1402 licensed to Allist Pharmaceuticals in China
  • 13 Jun 2010 Preclinical pharmacodynamics data presented at the 15th Congress of the European Hematology Association (EHA-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top